Atorvastatin improves peritoneal sclerosis induced by hypertonic PD solution in rats

Area of Science:

• Nephrology
• Pharmacology
• Biomedical Engineering

Background:

• Peritoneal sclerosis is a serious complication of peritoneal dialysis (PD), leading to ultrafiltration failure.
• It stems from chronic peritoneal injury caused by dialysis solution composition and recurrent peritonitis.
• Statins possess anti-inflammatory properties that may mitigate injury responses.

Purpose of the Study:

• To investigate the protective effects of atorvastatin against peritoneal alterations induced by hypertonic glucose solutions.
• To evaluate atorvastatin's capacity to modulate inflammatory responses in the peritoneal membrane.

Main Methods:

• Thirty-two non-uremic rats were divided into sham, hypertonic PD solution, and hypertonic PD solution plus atorvastatin groups.
• The study involved a four-week treatment period followed by a one-hour peritoneal equilibration test (PET).
• Key parameters measured included dialysate-to-plasma urea ratio, glucose reabsorption, ultrafiltration volume, and levels of TGF-β1 and VEGF.

Main Results:

• Atorvastatin administration preserved ultrafiltration volume and reduced peritoneal thickness compared to the hypertonic glucose group.
• The glucose gradient dissipated more rapidly in the dextrose-only group, indicating impaired glucose reabsorption.
• While TGF-β1 levels were higher in the dextrose group, atorvastatin treatment showed a trend towards normalization.

Conclusions:

• Hypertonic glucose solutions impair peritoneal transport and ultrafiltration, leading to peritoneal membrane alterations.
• Atorvastatin effectively prevented these detrimental changes, suggesting a protective role.
• The anti-inflammatory action of statins may be beneficial in protecting the peritoneal membrane during PD.